ChromoTek Nano-Traps with Nanobodies

Sunday, 01 August, 2021 | Supplied by: BioNovus Life Sciences

ChromoTek Nano-Traps with Nanobodies

The immunoprecipitation of very large proteins, oligomers or complexes and the Co-IP of bulky/multiple binding partners may be challenging when using porous beads. The size of the pores of agarose or magnetic agarose beads is limited and hence this may exclude molecules from diffusing into the pores and prevent effective interaction with the binding ligand. Also, the molecule’s shape may similarly limit diffusion into the pores. Therefore, binding can only occur on the outer surface of the agarose or magnetic agarose beads, which results in a poor immunoprecipitation performance.

ChromoTek’s Magnetic Particles M-270 are non-porous, solid particles with recombinant single domain VHH antibody (aka Nanobody) ligands coupled onto their surface. Hence all sizes of tagged proteins — including very large tagged proteins, oligomers and complexes, including bulky binding partners — will effectively bind to the Nanobodies coupled to the Magnetic Particles M-270, enabling simple and efficient immunoprecipitation.

Available from ChromoTek are three Nano-Traps with the Nanobody coupled to the Magnetic Particles M-270. These are the GFP-Trap, RFP-Trap and Spot-Trap.

ChromoTek’s range of available Nano-Traps with Nanobodies coupled to agarose beads, and in some cases also available coupled to magnetic agarose beads, include these Nano-Traps: GFP, GST, Halo, MBP, Mdm4/HdmX, MK2, mNeonGreen, Myc, p53-C-term, p53-N-term, PARP1, RFP, SNAP/SLIP-tag, Spot, TurboGFP and V5.

Online: www.bionovuslifesciences.com.au
Phone: 02 9484 0931
Related Products

Lumiprobe DusQ fluorescence quenchers

Lumiprobe offers a series of DusQ fluorescence quenchers with different spectral properties and...

Enzo Life Sciences SCREEN-WELL Epigenetics library

Enzo Life Sciences' SCREEN-WELL Epigenetics library contains 43 compounds with defined...

LSBio PathPlus Cancer Antibodies

The LSBio PathPlus Cancer series of antibodies include both well-established biomarkers of cancer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd